October 28, 2026
Viking Therapeutics trades at $3.1B with roughly $1B in cash, four active Phase 3 trials, and a dual-formulation obesity asset that no major pharma company owns yet
The CIA Discovered Strange Black Rocks Worth TRILLIONS
During a top-secret Cold War mission, they stumbled onto the largest concentration of critical metals ever found…
Over 21 BILLION tons of rare earths, cobalt, nickel and manganese.
According to my former CIA contact, Trump is about to begin harvesting this MOTHERLODE for America.
Click here to discover the $5 mining firm at the center of it all.
Strip out the roughly $1 billion in cash sitting on Viking’s balance sheet and the market is pricing VK2735, four concurrent Phase 3 trials, and a second obesity candidate in Phase 1 at somewhere around $2 billion. For the most advanced independent GLP-1/GIP obesity asset in the industry, that is a number that does not hold up to scrutiny.
What the Asset Actually Is
VK2735 is a dual GLP-1/GIP receptor agonist, the same mechanism as Lilly’s Zepbound. It delivered 14.7% weight loss after just 13 weekly doses in Phase 2, with no plateau observed. The oral formulation reached 12.2% at 13 weeks, with 80% of participants hitting at least 10% body weight reduction. Maintenance data released in September showed patients retained between 90% and 97% of their weight loss when transitioning off weekly injections.
Those are not marginal numbers. They are competitive with anything currently in late-stage development outside of Lilly’s own pipeline, and they come packaged in two formulations: a subcutaneous injection in the VANQUISH Phase 3 program, now fully enrolled, and an oral tablet in the SUNRISE Phase 3 program, launched October 14. Beyond VK2735, Viking initiated a Phase 1 study of VK3019, a dual amylin and calcitonin receptor agonist, in June, adding a second distinct obesity mechanism to the portfolio.
Write this date down, circle it on your calendar, whatever you need to do.
Dec. 18.
That’s when our research indicates OpenAI will release a confidential document.
When they do, likely around 4 p.m. just before the market closes …
It could kickstart a $40 trillion chasm.
Many investors will likely be caught off guard.
To make sure that’s not you, click here to find out all the crucial details.
The Metsera Benchmark
The reference deal is Pfizer’s acquisition of Metsera, completed November 13, 2025 for up to $10 billion, following a bidding war with Novo Nordisk that forced Pfizer to more than double its original $4.9 billion offer. Metsera’s lead asset was a monthly injectable GLP-1 receptor agonist beginning Phase 3. VK2735 has Phase 3 data that is further along, an oral formulation with Phase 2 results already in hand, and a maintenance dataset that answers one of the market’s biggest questions about GLP-1 durability. Viking’s current market cap of $3.1 billion is roughly 30% of what Pfizer paid for a comparable-stage asset a year ago.
The Pfizer/Metsera deal also confirmed that the FTC will intervene to preserve competition in this space. The commission effectively pushed the deal toward Pfizer precisely because Novo’s ownership of Metsera would have concentrated the market further. That dynamic matters for understanding who can realistically bid for Viking.
Who Is Left to Buy It
One idea. Backed by the analysts.
Join 130,000+ self-directed investors who get one trade idea a day, sourced from top Wall Street analysts and explained in plain English. Free, and a five-minute read.
Lilly holds roughly 59.5% of the U.S. obesity market between Mounjaro and Zepbound. Acquiring VK2735 almost certainly draws antitrust review at that market share level. Novo carries its own dominant incretin position. Both would face meaningful regulatory friction.
That leaves a cleaner path for buyers with obesity portfolio gaps. AstraZeneca spent $18.5 billion licensing a once-monthly GLP-1 from CSPC Pharmaceutical, a deal that gives it injectable coverage but no oral dual-agonist asset. Pfizer, now that the Metsera integration is underway, has MET-097i in Phase 3 but limited oral pipeline depth. Roche licensed Zealand Pharma’s amylin analog petrelintide for $5.3 billion and remains without a GLP-1/GIP oral asset. Any of the three would acquire a dual-formulation Phase 3 platform at a fraction of what comparable assets have cost over the past twelve months.
The Risk the Bulls Are Discounting
The valuation gap is real, but so is the data dependency. VANQUISH-1 top-line results are expected around mid-2027. Any slip in enrollment timelines, safety signal, or efficacy miss compresses the buyout premium sharply, because a late-stage asset that stumbles in Phase 3 is not the same asset at all. The 21-analyst consensus target of $95.05, more than three times the current price, assumes successful readouts. A buyout before those data points removes that binary risk for a buyer willing to pay for certainty.
That is, ultimately, the cleanest argument for a deal happening before mid-2027: every month that passes is a month closer to a data readout that either validates the asking price or eliminates the premium entirely. Buyers who want the asset without the Phase 3 risk have a narrowing window. The Polymarket contract implied a 38.5% probability of a Viking acquisition before 2027. That is not a consensus, but it is not noise either.
